Prognostication of non–small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio
Radiation Oncology Journal · 31.03.2026 · 44 (1) · 16-27
DOI: 10.3857/roj.2025.00570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 31.03.2026. Verfasst von Yi Han Xia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: University of British Columbia.
Abstract (Originalsprache)
Purpose
We evaluated neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor in patients with stage III unresectable non–small cell lung cancer (NSCLC) treated with concurrent chemoradiation (CRT). Furthermore, we examined neutrophil and lymphocyte changes to determine their contributions to NLR variation over time. Materials and Methods: A retrospective review was performed that included 262 patients diagnosed with stage III unresectable NSCLC from 2005 to 2020 who received concurrent CRT with a 60 Gy or 66 Gy in 30 fractions radiotherapy regimen. Pre-CRT NLR, lymphocyte nadir NLR, post-CRT NLR at 1 month ± 2-week intervals up to 6 months relative to the end of CRT, and NLR fold-change were calculated. The primary endpoint was overall survival.
Results
Of the examined parameters, high NLR had the most consistently high prognostic value for poorer outcomes for all 3 endpoints in the 6-month period post-CRT, with the highest hazard ratios (HRs) at 3 to 4 months. This was associated with a decrease in neutrophils from 3 to 4 months, while NLR and lymphocytes were relatively stable. Several other parameters at 4 months, including individual cell counts and NLR fold-change (relative to the lymphocyte nadir), were associated with high HRs for mortality.
Conclusion
Our study suggests that a window of time at 3 to 4 months post-CRT exists for when NLR and related hematologic parameters demonstrate increased prognostic value. This period may represent an area for further investigation as a potential opportunity for risk stratification with possible implications for surveillance and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- BC Cancer - Kelowna, Kelowna, BC, Canada.
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
Förderung
- University of British Columbia
Zitieren
APA
Xia, Y. H., Huang, L. T. H., Chang, J. S., Rao, S., Shafiee, A., & Atrchian, S. (2026). Prognostication of non–small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio. Radiation Oncology Journal, 44(1), 16-27. https://doi.org/10.3857/roj.2025.00570
Vancouver
Xia YH, Huang LTH, Chang JS, Rao S, Shafiee A, Atrchian S. Prognostication of non–small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio. Radiation Oncology Journal. 2026;44(1):16-27. doi:10.3857/roj.2025.00570
BibTeX
@article{Xia2026,
author = {Xia, Yi Han and Huang, Luo Ting Helen and Chang, Jee Suk and Rao, Sanjay and Shafiee, Amir and Atrchian, Siavash},
title = {Prognostication of non–small cell lung cancer with concurrent chemoradiation treatment using neutrophil-to-lymphocyte ratio},
journal = {Radiation Oncology Journal},
year = {2026},
volume = {44},
number = {1},
pages = {16--27},
doi = {10.3857/roj.2025.00570}
}
EUVIMED